askg315
Recombinant proteinexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 9, 2022 (NCT05509985)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-15Supplementation
IL15 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05554666 | Phase 1 | Oct 31, 2022 | AskGene Pharma, Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd. |
| NCT05509985 | Phase 1 | Sep 9, 2022 | AskGene Pharma, Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AskGene Pharma, Inc. | For profit | 2 | 2 | 1 | 2022 |
| Jiangsu Aosaikang Pharmaceutical Co., Ltd. | For profit | 2 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1